2 completed, 1 terminated, 1 withdrawn. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
Follow Inozyme Pharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The ENABLE Study: Safety and Efficacy Study of INZ-701 in Patients With ENPP1 Deficiency INZ-701 - Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets | Phase 2 | Withdrawn | Inozyme Pharma | 2025-01-31 | 2025-05-01 | |
| ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency INZ-701 - Gene Mutations, Pseudoxanthoma Elasticum | Phase 2 | Terminated | Inozyme Pharma | 22 | 2024-06-19 | 2026-10-19 |
| Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXE INZ-701 - ATP-Binding Cassette Subfamily C Member 6 Deficiency, Pseudoxanthoma Elasticum | Phase 1 / Phase 2 | Completed | Inozyme Pharma | 10 | 2022-04-11 | 2026-10-13 |
| Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency INZ-701 - Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets | Phase 1 / Phase 2 | Completed | Inozyme Pharma | 13 | 2021-11-21 | 2026-10-27 |
Arterial calcification of infancy (4) · Hypophosphatemic Rickets, Autosomal Recessive, 1 (2) · Pseudoxanthoma Elasticum (2)
United Kingdom (3) · United States (3) · France (2) · Germany (2) · Canada (1)
Kurt Gunter, MD (1)